Indivior’s share price has been on a roller coaster ride over the past year. The stock is down more than 60% from its 52-week high, and investors are wondering if the worst is over for the struggling pharmaceutical company.
Indivior was once a high-flying stock, but it has come under intense pressure in recent years.
The company is best known for its opioid addiction treatment Suboxone, which generated billions of dollars in annual sales at its peak. However, generic competition has decimated Suboxone’s sales, and Indivior has been unable to offset those losses with other products.
The company has been hit with several lawsuits and investigations related to its marketing of Suboxone, and it faces an uphill battle to turnaround its business.
Indivior’s share price reflects these challenges, and investors are wondering if the stock is a value play or a value trap.
Indivior, a pharmaceutical company specializing in addiction treatment, has seen its share price tumble in recent months. The stock is down nearly 60% from its 52-week high, and some analysts are wondering if the company is in trouble.
So what’s going on with Indivior?
There are a few potential explanations for the stock’s woes. First, generic competition is eating into sales of Suboxone Film, Indivior’s flagship product. Suboxone Film is an oral film that dissolves under the tongue and is used to treat opioid addiction.
Generic versions of the drug were approved by the FDA last year, and they’re already starting to eat into Indivior’s market share.
Second, Indivior is facing mounting legal troubles. The company is currently under investigation by the DOJ for allegedly misleading doctors and patients about the risks of Suboxone Film.
If Indivior is found guilty of wrongdoing, it could face hefty fines or even jail time for its executives.
Lastly, Indivior faces stiff competition from other companies in the addiction treatment space. Vivitrol (naltrexone) from Alkermes and Bunavail (buprenorphine/naloxone) from BioDelivery Sciences are both strong competitors to Suboxone Film, and they’re both approved for use in treating opioid addiction.
So what does the future hold for Indivior? That remains to be seen. The company still has a strong product portfolio and a good pipeline of new products in development.
But with generic competition eating into sales of its flagship product and legal troubles looming large, it’s hard to say if Indivior will be able to turn things around anytime soon.
Reckitt Benckiser Share Price
Reckitt Benckiser Group PLC (LON:RB) shares fell on Thursday morning after the company announced it was recalling its popular heartburn drug Zantac in the United States.
The news sent Reckitt’s stock tumbling as much as 6% in early trading, making it one of the biggest fallers on London’s blue-chip index.
The U.S. Food and Drug Administration said on Wednesday that it had found “unacceptable levels” of a cancer-causing substance in some samples of Zantac, also known generically as ranitidine.
The FDA has not yet concluded that Zantac causes cancer, but said it is investigating the matter further.
Reckitt said in a statement that it was voluntarily recalling all over-the-counter and prescription versions of Zantac in the United States “as a precaution.” It will stop distributing the drug while the recall is underway.
“Patient safety is our first priority and we are committed to working with regulators in an open and transparent way,” Rakesh Kapoor, Reckitt’s chief executive, said in the statement.
Credit: www.fiercebiotech.com
What is the Current Share Price of Indivior
Indivior is a global pharmaceutical company that develops, manufactures and markets prescription drugs for the treatment of addiction and mental health disorders. The company’s share price is $8.17 as of March 28, 2019.
How Has Indivior’S Share Price Performed Over Time
Indivior’s share price has been on a roller coaster ride over the last few years. In 2015, the stock was trading at around $35 per share. By early 2016, the stock had more than doubled to trade above $70 per share.
However, the stock then plunged in value and was trading below $30 per share by early 2017. The stock then rallied strongly and was back above $70 per share by early 2018. However, the stock has once again fallen sharply in value and is currently trading at around $45 per share.
What Factors Have Influenced Indivior’S Share Price in the Past
Indivior’s share price has been influenced by a number of factors, including the company’s financial performance, regulatory environment, and competitive landscape.
The company has faced challenges in recent years due to declining sales of its flagship product, Suboxone Film. Suboxone Film is a treatment for opioid dependence and faces competition from generic versions of the drug.
In response to the decline in sales, Indivior has focused on expanding its portfolio of products and launching new initiatives to drive growth.
The company has also been impacted by the changing regulatory environment for opioid treatments. The US Food and Drug Administration (FDA) has issued new guidance on the use of opioids, which could impact demand for Suboxone Film.
Indivior is also facing investigations by the US Department of Justice (DOJ) and Securities and Exchange Commission (SEC). These investigations are ongoing and it is unclear what the outcome will be.
The competitive landscape for Indivior’s products is also evolving.
The FDA recently approved several new drugs for treating opioid dependence, which could increase competition for Suboxone Film. Indivior is also facing increased competition from generic manufacturers who are seeking to enter the market with their own versions of Suboxone Film.
Indivior’s share price will continue to be influenced by these various factors in the coming months and years.
Where Can I Find Historical Data on Indivior’S Share Price
Indivior is a pharmaceutical company that specializes in the treatment of addiction and mental illness. The company’s share price is not as well-documented as some other publicly traded companies, but there are still a few ways to access historical data. One way is to use a financial website like Yahoo Finance or Google Finance.
Another way is to look up the company’s stock symbol (INDV) on an online stock exchange like the Nasdaq or the London Stock Exchange. Finally, Indivior’s own website has a section devoted to investor relations, which includes some historical share price information.
Are There Any Analysts Covering Indivior Shares
As of October 2019, there are eight analysts covering Indivior shares, according to Reuters.
Indivior is a pharmaceutical company focused on developing treatments for substance abuse and mental health disorders. The company’s main product is Suboxone, a treatment for opioid addiction.
The analysts have set the following price targets for Indivior shares:
– Barclays: $7.00
– Berenberg: $4.80
– Credit Suisse: $6.50
– Deutsche Bank: $5.70
– Exane BNP Paribas: $6.30
– Jefferies: $7.50
Three AIM stocks we own and two we have avoided
Conclusion
Indivior shares fell sharply on Thursday after the U.S. Department of Justice unsealed a criminal indictment accusing the company of misleading doctors and patients about the risks of its opioid addiction treatment Suboxone Film.
The DOJ alleges that Indivior engaged in a years-long scheme to boost prescriptions of Suboxone Film by misrepresenting its safety and efficacy, leading to more than $1 billion in false claims to government health care programs.
Indivior has denied any wrongdoing, saying it will “vigorously defend” itself against the charges.
If convicted, the company faces up to $3 billion in fines.
